May 14, 2020 / 3:48 PM / 16 days ago

BRIEF-Nordic Nanovector's Betalutin Receives Positive Opinion For Orphan Drug Designation From EMA For Marginal Zone Lymphoma

May 14 (Reuters) - Nordic Nanovector ASA:

* NORDIC NANOVECTOR’S BETALUTIN® RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FROM EMA FOR MARGINAL ZONE LYMPHOMA (MZL) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below